Majumder S, Mishra S, Shinde N, Cuitino M, Bauer M, Ahirwar D
Breast Cancer Res. 2025; 27(1):1.
PMID: 39754221
PMC: 11697808.
DOI: 10.1186/s13058-024-01933-3.
Tahara S, Rentsch S, DE Faria F, Sarchet P, Karna R, Calore F
Oncol Res. 2024; 33(1):1-13.
PMID: 39735679
PMC: 11671414.
DOI: 10.32604/or.2024.053635.
Li Z, You Y, Feng B, Chen J, Gao H, Li F
Oncol Rev. 2024; 18:1434981.
PMID: 39600908
PMC: 11588466.
DOI: 10.3389/or.2024.1434981.
Liu P, Jacques J, Hwang C
Epigenomes. 2024; 8(4).
PMID: 39584964
PMC: 11587027.
DOI: 10.3390/epigenomes8040041.
Yang J, Zhang J, Gu J, Gao M, Zheng M, Guo S
World J Gastroenterol. 2024; 30(42):4532-4543.
PMID: 39563744
PMC: 11572629.
DOI: 10.3748/wjg.v30.i42.4532.
Non-small cell lung cancer organoids: Advances and challenges in current applications.
Wu M, Liao Y, Tang L
Chin J Cancer Res. 2024; 36(5):455-473.
PMID: 39539817
PMC: 11555200.
DOI: 10.21147/j.issn.1000-9604.2024.05.01.
Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy.
Hicks W, Gattie L, Shami M, Traylor J, Davar D, Najjar Y
Sci Rep. 2024; 14(1):24843.
PMID: 39438602
PMC: 11496643.
DOI: 10.1038/s41598-024-76583-8.
Mimicking and analyzing the tumor microenvironment.
Crouigneau R, Li Y, Auxillos J, Goncalves-Alves E, Marie R, Sandelin A
Cell Rep Methods. 2024; 4(10):100866.
PMID: 39353424
PMC: 11573787.
DOI: 10.1016/j.crmeth.2024.100866.
Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models.
Goncalves B, Liu S, Zhang X, Fan A, Ou L, Xu X
J Vis Exp. 2024; (211).
PMID: 39311587
PMC: 11539850.
DOI: 10.3791/66509.
Organoid as a promising tool for primary liver cancer research: a comprehensive review.
Hu X, Wei J, Liu P, Zheng Q, Zhang Y, Zhang Q
Cell Biosci. 2024; 14(1):107.
PMID: 39192365
PMC: 11348559.
DOI: 10.1186/s13578-024-01287-5.
Establishment of Primary Cell Cultures from Canine Oral Melanomas via Fine-Needle Aspiration: A Novel Tool for Tumorigenesis and Cancer Progression Studies.
Lo Giudice A, Porcellato I, Pellegrini M, Rottenberg S, He C, Dentini A
Animals (Basel). 2024; 14(13).
PMID: 38998060
PMC: 11240394.
DOI: 10.3390/ani14131948.
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment.
Polak R, Zhang E, Kuo C
Nat Rev Cancer. 2024; 24(8):523-539.
PMID: 38977835
DOI: 10.1038/s41568-024-00706-6.
TTK inhibitor OSU13 promotes immunotherapy responses by activating tumor STING.
Bharti V, Kumar A, Wang Y, Roychowdhury N, de Lima Bellan D, Kassaye B
JCI Insight. 2024; 9(15).
PMID: 38900577
PMC: 11383830.
DOI: 10.1172/jci.insight.177523.
A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine.
Kalla J, Pfneissl J, Mair T, Tran L, Egger G
Cell Oncol (Dordr). 2024; 48(1):1-26.
PMID: 38806997
PMC: 11850459.
DOI: 10.1007/s13402-024-00960-8.
Wnt/β-catenin signaling is a therapeutic target in anaplastic thyroid carcinoma.
Diaz D, Bergdorf K, Loberg M, Phifer C, Xu G, Sheng Q
Endocrine. 2024; 86(1):114-118.
PMID: 38806891
PMC: 11444896.
DOI: 10.1007/s12020-024-03887-0.
Developing more comprehensive thyroid cancer organoids for precision medicine.
Yang H, Chen D
Hum Cell. 2024; 37(4):1229-1230.
PMID: 38684639
DOI: 10.1007/s13577-024-01070-1.
Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy.
Hicks W, Gattie L, Traylor J, Davar D, Najjar Y, Richardson DO T
bioRxiv. 2024; .
PMID: 38328251
PMC: 10849477.
DOI: 10.1101/2024.01.18.576318.
Advances in the Construction and Application of Thyroid Organoids.
Zhang Y, Fu M, Wang H, Sun H
Physiol Res. 2023; 72(5):557-564.
PMID: 38015755
PMC: 10751051.
DOI: 10.33549/physiolres.935102.
Bioengineered skin organoids: from development to applications.
Hong Z, Zhu S, Li H, Luo J, Yang Y, An Y
Mil Med Res. 2023; 10(1):40.
PMID: 37605220
PMC: 10463602.
DOI: 10.1186/s40779-023-00475-7.
Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment.
Anderle N, Schafer-Ruoff F, Staebler A, Kersten N, Koch A, Onder C
J Exp Clin Cancer Res. 2023; 42(1):210.
PMID: 37596623
PMC: 10436441.
DOI: 10.1186/s13046-023-02782-2.